Yousif Capital Management LLC Sells 18,250 Shares of Takeda Pharmaceutical Co. (NYSE:TAK)

Yousif Capital Management LLC reduced its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 37.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,869 shares of the company's stock after selling 18,250 shares during the period. Yousif Capital Management LLC's holdings in Takeda Pharmaceutical were worth $444,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. QRG Capital Management Inc. increased its stake in Takeda Pharmaceutical by 16.8% in the 4th quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock valued at $4,364,000 after buying an additional 47,490 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Takeda Pharmaceutical by 48.6% in the 4th quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock valued at $600,000 after acquiring an additional 14,831 shares in the last quarter. US Bancorp DE grew its holdings in shares of Takeda Pharmaceutical by 21.2% in the 4th quarter. US Bancorp DE now owns 124,332 shares of the company's stock valued at $1,646,000 after acquiring an additional 21,744 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Takeda Pharmaceutical by 60.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 181,929 shares of the company's stock valued at $2,409,000 after acquiring an additional 68,200 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in Takeda Pharmaceutical by 29.2% during the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock worth $69,000 after acquiring an additional 1,045 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 2.5%

TAK traded up $0.38 during trading on Tuesday, reaching $15.10. 2,277,201 shares of the stock were exchanged, compared to its average volume of 1,954,933. The stock has a market cap of $48.03 billion, a P/E ratio of 68.62 and a beta of 0.23. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.52 and a current ratio of 1.01. The stock's 50 day moving average price is $14.80 and its two-hundred day moving average price is $14.21. Takeda Pharmaceutical Co. has a twelve month low of $12.78 and a twelve month high of $15.43.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. The firm had revenue of $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. Equities analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.